Nicolas Portelange
Research Subjects
Nicolas Portelange has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Wim Weyenberg
KiOmed Pharma, Herstal, Belgium
2 shared publicationsChristoph Eichhorn
Praxiszentrum Elisengalerie, Aachen, Germany
1 shared publicationD. Haverkamp
1 shared publicationG. Skaliczki
1 shared publicationJ. Bentin
1 shared publicationM. Chausson
1 shared publication
Latest Publications
- Open Access
- 4 April 2025
- Published by Elsevier in Osteoarthritis and Cartilage Open
- Vol. 7 (2) , 100605
Twelve-month efficacy of carboxymethyl-chitosan in refractory knee osteoarthritis: A randomized controlled trial (PIONEER)
- 4 April 2025
- Published by Elsevier in Osteoarthritis and Cartilage Open
- Vol. 7 (2) , 100605
Open AccessTwelve-month efficacy of carboxymethyl-chitosan in refractory knee osteoarthritis: A randomized controlled trial (PIONEER)
- Open Access
- 18 March 2024
- Published by Springer Nature in Rheumatology and Therapy
- Vol. 11 (3) , 649-662
Long-Term Efficacy Following Intra-articular Injection of Carboxymethyl-chitosan, a New Product Class for Knee Osteoarthritis: Results from an Observational Study in Germany
Introduction Evaluate the real-world efficacy of a single intra-articular injection of carboxymethyl-chitosan (CM-chitosan), a new product class for knee osteoarthritis (OA). Methods This post-marketing study included adult patients with knee OA, who received a single injection of 60 mg CM-chitosan (currently marketed as KioMedinevsone) according to the instructions for use. Follow-up was performed at weeks 1, 12, 24, and 36. Efficacy was evaluated using a Visual Analog Scale (VAS) score for pain, the Knee injury and Osteoarthritis Outcome Score (KOOS), Patient’s Global Assessment (PGA), and overall patient satisfaction. Results Forty-nine patients were included in the study. VAS pain score significantly decreased from a median of 49.0 mm at baseline to 24.0 mm at week 1 and to 18 mm at week 36. Pain improvement was stable since at week 36; 91.8% of patients confirmed pain reduction. All KOOS subscales (symptoms, pain, activities of daily living, sports and recreational activities, quality of life) improved significantly compared to baseline at all time points. KOOS pain improved progressively from a median of 58.3% at baseline (mean 56.2 ± 18.8%) to 86.1% (mean 74.1 ± 24%) at week 36 compared to baseline. Overall, more than 70% of patients reported a condition gain (PGA), matching well with the more than 75% of patients being satisfied with the treatment. At 6 months, 72.7% of the patients could be classified as responder according to the OMERACT-OARSI proposed set of responder criteria. Conclusion CM-chitosan showed a rapid onset of pain relief after 1 week and with a duration of 9 months. In a real-world setting, treatment with CM-chitosan would appear to be a potentially effective option to reduce pain and improve physical function and global condition in patients with knee OA, opening new perspectives in patients who are considered as refractory to current symptomatic therapies and where the unmet need is high. Trial Registration Number NCT04757051 (ClinicalTrials.gov).
- 18 March 2024
- Published by Springer Nature in Rheumatology and Therapy
- Vol. 11 (3) , 649-662
Open AccessLong-Term Efficacy Following Intra-articular Injection of Carboxymethyl-chitosan, a New Product Class for Knee Osteoarthritis: Results from an Observational Study in Germany
Introduction Evaluate the real-world efficacy of a single intra-articular injection of carboxymethyl-chitosan (CM-chitosan), a new product class for knee osteoarthritis (OA). Methods This post-marketing study included adult patients with knee OA, who received a single injection of 60 mg CM-chitosan (currently marketed as KioMedinevsone) according to the instructions for use. Follow-up was performed at weeks 1, 12, 24, and 36. Efficacy was evaluated using a Visual Analog Scale (VAS) score for pain, the Knee injury and Osteoarthritis Outcome Score (KOOS), Patient’s Global Assessment (PGA), and overall patient satisfaction. Results Forty-nine patients were included in the study. VAS pain score significantly decreased from a median of 49.0 mm at baseline to 24.0 mm at week 1 and to 18 mm at week 36. Pain improvement was stable since at week 36; 91.8% of patients confirmed pain reduction. All KOOS subscales (symptoms, pain, activities of daily living, sports and recreational activities, quality of life) improved significantly compared to baseline at all time points. KOOS pain improved progressively from a median of 58.3% at baseline (mean 56.2 ± 18.8%) to 86.1% (mean 74.1 ± 24%) at week 36 compared to baseline. Overall, more than 70% of patients reported a condition gain (PGA), matching well with the more than 75% of patients being satisfied with the treatment. At 6 months, 72.7% of the patients could be classified as responder according to the OMERACT-OARSI proposed set of responder criteria. Conclusion CM-chitosan showed a rapid onset of pain relief after 1 week and with a duration of 9 months. In a real-world setting, treatment with CM-chitosan would appear to be a potentially effective option to reduce pain and improve physical function and global condition in patients with knee OA, opening new perspectives in patients who are considered as refractory to current symptomatic therapies and where the unmet need is high. Trial Registration Number NCT04757051 (ClinicalTrials.gov).
- Open Access
- 14 February 2023
- Published by Bentham Science Publishers Ltd. in The Open Rheumatology Journal
- Vol. 17 (1)
KiOmedine® CM-Chitosan is Effective for Treating Advanced Symptomatic Knee Osteoarthritis up to Six Months Following a Single Intra-Articular Injection: A Post Hoc Analysis of Aproove Clinical Study
Background: Symptomatic knee osteoarthritis (OA) is typically treated with hyaluronan-based intra-articular injections. Advanced knee OA patients are often unresponsive to hyaluronan. KiOmedine® Carboxymethyl-Chitosan (CM-Chitosan), a novel fluid implant, was safe and effective for treating symptomatic knee OA. Objective: The objective of this study is to describe the efficacy of a single injection of KiOmedine® CM-Chitosan in advanced knee OA. Methods: Patients with advanced knee OA enrolled in the APROOVE trial and treated with KiOmedine® CM-Chitosan were identified: subgroup-1, BMI >30 kg/m2 and/or Kellgren Lawrence (KL) grade III (n=39), and subgroup-2, BMI >30 kg/m2 and KL-grade III (n=8). Within-group analyses were performed using the WOMAC scores and OMERACT-OARSI responder criteria at 3 and 6 months. Results: In both subgroups, significant improvements in all WOMAC scores were observed at 3 and 6 months (p® CM-Chitosan could be an effective therapeutic option for patients with advanced knee OA. Clinical trial registration number: Clinicaltrial.gov identifier: Net30679208.
- 14 February 2023
- Published by Bentham Science Publishers Ltd. in The Open Rheumatology Journal
- Vol. 17 (1)
Open AccessKiOmedine® CM-Chitosan is Effective for Treating Advanced Symptomatic Knee Osteoarthritis up to Six Months Following a Single Intra-Articular Injection: A Post Hoc Analysis of Aproove Clinical Study
Background: Symptomatic knee osteoarthritis (OA) is typically treated with hyaluronan-based intra-articular injections. Advanced knee OA patients are often unresponsive to hyaluronan. KiOmedine® Carboxymethyl-Chitosan (CM-Chitosan), a novel fluid implant, was safe and effective for treating symptomatic knee OA. Objective: The objective of this study is to describe the efficacy of a single injection of KiOmedine® CM-Chitosan in advanced knee OA. Methods: Patients with advanced knee OA enrolled in the APROOVE trial and treated with KiOmedine® CM-Chitosan were identified: subgroup-1, BMI >30 kg/m2 and/or Kellgren Lawrence (KL) grade III (n=39), and subgroup-2, BMI >30 kg/m2 and KL-grade III (n=8). Within-group analyses were performed using the WOMAC scores and OMERACT-OARSI responder criteria at 3 and 6 months. Results: In both subgroups, significant improvements in all WOMAC scores were observed at 3 and 6 months (p® CM-Chitosan could be an effective therapeutic option for patients with advanced knee OA. Clinical trial registration number: Clinicaltrial.gov identifier: Net30679208.